Cost-effectiveness of the Endeavor stent in de novo native coronary artery lesions updated with contemporary data

EuroIntervention

Volumn 5, Issue 7, 2010, Pages 826-832

  Remak, Edit ^a   Manson, Stephanie ^a   Hutton, John ^a   Brasseur, Pascale ^b   Olivier, Elaine ^c   Gershlick, Anthony ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Medtronic Ltd   (United Kingdom)

^c UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

Cost effectiveness; Drug eluting stent; Zotarolimus eluting stent

Indexed keywords

CLOPIDOGREL; ZOTAROLIMUS; CARDIOVASCULAR AGENT; DRUG DERIVATIVE; METAL; RAPAMYCIN;

ACUTE HEART INFARCTION; ARTICLE; BARE METAL STENT; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG ELUTING STENT; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; META ANALYSIS; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; HEALTH CARE COST; HEART INFARCTION; INSTRUMENTATION; PROBABILITY; PROSTHESIS; PUBLIC HEALTH; STATISTICAL MODEL; STENT; THROMBOSIS; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; UNITED KINGDOM;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG-ELUTING STENTS; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; METALS; MODELS, ECONOMIC; MYOCARDIAL INFARCTION; NATIONAL HEALTH PROGRAMS; PROSTHESIS DESIGN; QUALITY-ADJUSTED LIFE YEARS; SIROLIMUS; STENTS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955953179     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV5I7A138     Document Type: Article

References (46)

1. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents: a hierarchical Bayesian meta-analysis. Ann Intern Med 2003;138: 777-786.
2. Brophy JM, Erickson LJ. Cost-effectiveness of drug-eluting coronary stents in Quebec, Canada. Int J Technol Assess Health Care 2005;21:326-333. (Pubitemid 41099213)
3. Fattori, Piva T. Drug-eluting stents in vascular intervention. Lancet 2003;361:247-9.
4. Jenkins NP, Prendergast BD, Thomas M. Drug eluting stents. BMJ 2002;325:1315-6.
5. Pocock SJ, Lansky AJ, Mehran R, Popma JJ, Fahy MP, Na Y, Dangas G, Moses JW, Pucelikova T, Kandzari DE, Ellis SG, Leon MB, Stone GW. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol 2008;51:23-32.
6. Hill RA, Boland A, Dickson R, Dündar Y, Haycox A, McLeod C, Mujica Mota R, Walley T, Bagust A. Drug-eluting stents: a systematic review and economic evaluation. Health Technol Assess 2007;11:iii-xi221.
7. Gershlick A, Kandzari DE, Leon MB, Wijns W, Meredith IT, Fajadet J, Popma JJ, Fitzgerald PJ, Kuntz RE; ENDEAVOR Investigators. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients. Am J Cardiol 2007;100:45M-55M.
8. Gao RL, Xu B, Chen JL, Yang YJ, Qiao SB, Li JJ, Qin XW, Yao M, Liu HB, Wu YJ, Yuan JQ, Chen J. Immediate and long-term outcomes of drug-eluting stent implantation for unprotected left main coronary artery disease: comparison with bare-metal stent implantation. Am Heart J 2008;155:553-61.
9. Zakliczynski M, Lekston A, Osuch M, Swierad M, Nadziakiewicz P, Przybylski R, Zembala M. Comparison of long-term results of drug-eluting stent and bare metal stent implantation in heart transplant recipients with coronary artery disease. Transplant Proc 2007;39:2859-61. (Pubitemid 350088098)
10. Brunner-La Rocca HP, Kaiser C, Bernheim A, Zellweger MJ, Jeger R, Buser PT, Osswald S, Pfisterer M; BASKET Investigators. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitäts Trial (BASKET): an 18-month analysis. Lancet 2007;370:1552-9. (Pubitemid 350018894)
11. Bakhai A, Stone GW, Mahoney E, Lavelle TA, Shi C, Berezin RH, Lahue BJ, Clark MA, Lacey MJ, Russell ME, Ellis SG, Hermiller JB, Cox DA, Cohen DJ; TAXUS-IV Investigators. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. J Am Coll Cardiol 2006;48:253-61. (Pubitemid 44026660)
12. Kaiser C, Brunner-La Rocca H, Buser P, Bonetti P, Osswald S, Linka A, Bernheim A, Zellweger M, Grize L, Pfisterer ME, BASKET Investigators. Incremental costeffectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a realworld setting: Randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet 2005;366:921-9. (Pubitemid 41265666)
13. van Hout BA, Serruys PW, Lemos PA, van den Brand M, van Es GA, Lindeboom WK, Morice MC. One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial. Heart 2005;91:507-12. (Pubitemid 40432784)
14. Mittmann N, Brown A, Seung SJ, Coyle D, Cohen E, Brophy J, Title L, Oh P. Economic evaluation of drug eluting stents [Technology report no 53]. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2005. https://www.ccohta.ca/publications/pdf/272-drug-eluting-stents-tr-e.pdf (13 March 2008)
15. Cohen DJ, Bakhai A, Shi CX, Githiora L, Lavelle T, Berezin RH, Leon MB, Moses JW, Carrozza JP, Zidar JP, Kuntz RE, SIRIUS Investigators. Cost-effectiveness of sirolimuseluting stents for treatment of complex coronary stenoses - results from the sirolimus-eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions (SIRIUS) trial. Circulation 2004;110: 508-14. (Pubitemid 39031165)
16. Bagust A, Grayson AD, Palmer ND, Perry RA, Walley T. Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study. Heart 2006;92:68-74. (Pubitemid 43021858)
17. Kirtane AJ, Ellis SG, Dawkins KD, Colombo A, Grube E, Popma JJ, Fahy M, Leon MB, Moses JW, Mehran R, Stone GW. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J Am Coll Cardiol 2008;51:708-15. (Pubitemid 351227416)
18. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. June 2008. www.nice.org.uk (10 July 2008)
19. Meredith I, Ormiston J, Whitbourn R, Kay I, Muller D, Bonan R, Popma J, Cutlip D, Fitzgerald P, Prpic R, Kuntz R. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention 2005;2:157-164.
20. Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, Popma JJ, Cutlip DE, Fitzgerald PJ; ENDEAVOR I Investigators. Four-year clinical follow- up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study. Am J Cardiol 2007;100:56M-61M.
21. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE. Randomized, doubleblind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006;114:798-806. (Pubitemid 44268230)
22. Schultheiss HP, Grube E, Kuck KH, Suttorp MJ, Heuer H, Bonnier H, Popma JJ, Kuntz RE, Fadajet J, Wijns W. Safety of direct stenting with the Endeavor stent: results of the Endeavor II continued access registry. EuroIntervention 2007;3:76-81.
23. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz RE, ENDEAVOR III Investigators. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006;48:2440-2447. (Pubitemid 44881222)
24. Jain AK, Meredith IT, Lotan C, Rothman MT, Pateraki S; E-Five Investigators. Real-world safety and efficacy of the endeavor zotarolimus-eluting stent: early data from the E-Five Registry. Am J Cardiol 2007;100:77M-83M.
25. FDA Executive Summary Memorandum. P060033. Endeavor Zotarolimus Drug-Eluting Coronary Stent System & Over-the-Wire (OTW), Rapid Exchange (RX), and Multi-Exchange II (MX2) Stent Delivery Systems. 2007. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4322b1-02-FDA- Executive%20Summary.pdf (6 March 2008).
26. Kiemeneij F, Serruys PW, Macaya C, Rutsch W, Heyndrickx G, Albertsson P, Fajadet J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, Disco CM, Morel MA. Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial. J Am Coll Cardiol 2001;37:1598-603.
27. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008. (Pubitemid 46376800)
28. Oostenbrink J, Tangelder M, Busschbach J, Van Hout BA, Buskens E, Algra A, Lawson J, Eikelboom B, Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study Group. Costeffectiveness of oral anticoagulants versus aspirin in patients with infrainguinal bypass grafting surgery. J Vasc Surg 2001;34:254-62. (Pubitemid 33661122)
29. Niemela K. MILESTONE II: a multicenter global observational registry with TAXUS EXPRESS2 paclitaxel eluting stent system. Presented at the TEAM Congress. 2004.
30. Thomas M. Are drug eluting stents really worth the money? Heart 2006;92:5-7.
31. Legrand VMG, Serruys PW, Unger F, van Hout BA, Vrolix MC, Fransen GM, Nielsen TT, Paulsen PK, Gomes RS, de Queiroz e Melo JM, Neves JP, Lindeboom W, Backx B, Arterial Revascularization Therapy Study (ARTS) Investigators. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 2004;109:1114-20.
32. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schönberger JP, Buller N, Bonser R, van den Brand MJ, van Herwerden LA, Morel MA, van Hout BA; Arterial Revascularization Therapies Study Group. Comparison of coronary artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-24. (Pubitemid 32285232)
33. Hill R, Bagust A, Bakhai A, Dickson R, Dündar Y, Haycox A, Mujica Mota R, Reaney A, Roberts D, Williamson P, Walley T. Coronary artery stents: a rapid systematic review and economic evaluation. Health Technol Assess 2004;8:iii-iv, 1-242.
34. Department of Health. National Health Service (NHS) Reference Costs 2005-06. Appendix NSRC4: NHS Trust & PCT Combined Reference Cost Schedules. Available at: http://www.dh.gov.uk/assetRoot/ 04/14/10/61/04141061.xls
35. British National Formulary 2008 (BNF). Available at: http://www.bnf.org/
36. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008;26: 733-44.
37. Babapulle MN, Joseph L, Bélisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004;364:583-91. (Pubitemid 39094175)
38. Singh M, Gersh BJ, McClelland RL, Ho KK, Willerson JT, Penny WF, Holmes DR Jr. Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. J Am Coll Cardiol 2005;45:198-203. (Pubitemid 40094725)
39. Nikolsky E, Kosinski E, Mishkel GJ, Kimmelstiel C, McGarry TF Jr, Mehran R, Leon MB, Russell ME, Ellis SG, Stone GW. Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial). Am J Cardiol 2005;95:709-15. (Pubitemid 40332647)
40. Ellis SG, Bajzer CT, Bhatt DL, Brener SJ, Whitlow PL, Lincoff AM, Moliterno DJ, Raymond RE, Tuzcu EM, Franco I, Dushman-Ellis S, Lander KJ, Schneider JP, Topol EJ. Real-world bare metal stenting: identification of patients at low or very low risk of 9-month coronary revascularization. Catheter Cardiovasc Interv 2004;63:135-40. (Pubitemid 39313401)
41. West NE, Ruygrok PN, Disco CM, Webster MW, Lindeboom WK, O'Neill WW, Mercado NF, Serruys PW. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 2004;109:867-73. (Pubitemid 38252739)
42. Iakovou I, Mintz GS, Dangas G, Abizaid A, Mehran R, Lansky AJ, Kobayashi Y, Hirose M, Ashby DT, Stone GW, Moses JW, Leon MB. Optimal final lumen area and predictors of target lesion revascularization after stent implantation in small coronary arteries. Am J Cardiol 2003;92:1171-6. (Pubitemid 37377826)
43. Kastrati A, Schömig A, Elezi S, Schühlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neumann FJ. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997;30:1428-36. (Pubitemid 27486458)
44. Togni M, Windecker S, Meier B. Treatment of restenosis. Curr Interv Cardiol Rep 2001;3:306-310.
45. Mishkel GJ, Moore AL, Markwell S, Shelton ME. Correlates of late and very late thrombosis of drug eluting stents. Am Heart J 2008;156:141-7.
46. National Institute for Health and Clinical Excellence. Coronary Artery Disease - Drug-Eluting Stents: Costing Template. Available at: http://www.nice.org.uk/Guidance/TA152/CostTemplate/xls/English